Snapshot

The Great Britain Marketing Authorisations under exceptional circumstances pathway has been developed by the Medicines and Healthcare products Regulatory Agency (MHRA) of United Kingdom.

This pathway can be used where Medicines where a comprehensive data package cannot be provided, because the condition to be treated is rare or because collection of full information is not possible or is unethical..

This pathway accelerates the regulatory review process.

It is an abridged review (a reliance pathway).

Info not found.